Uy, G L
Duncavage, E J
Chang, G S
Jacoby, M A
Miller, C A
Shao, J
Heath, S
Elliott, K
Reineck, T
Fulton, R S
Fronick, C C
O'Laughlin, M
Ganel, L
Abboud, C N
Cashen, A F
DiPersio, J F
Wilson, R K
Link, D C
Welch, J S
Ley, T J
Graubert, T A
Westervelt, P
Walter, M J
Article History
Received: 7 June 2016
Revised: 1 September 2016
Accepted: 6 September 2016
First Online: 14 October 2016
Competing interests
: GLU has received compensation as a consultant for Novartis. The other authors declare no conflict of interest.